Scientific recommendation on classification of advanced therapy medicinal products


Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

Brief description (or name where available) of the active substance(s)

Irradiated, allogeneic pancreatic tumour cells

Brief description of the finished product

Two irradiated allogeneic pancreatic tumour cell lines, genetically engineered to secrete human granulocyte macrophage-colony stimulating factor (GM-CSF)

Proposed indication

Treatment of pancreatic cancer

EMA/CAT conclusion

The committee adopted on 3rd March 2016 the following scientific recommendation.

On the basis that:

The Product

- contains an active substance which consists of a recombinant nucleic acid used in human beings with a view to adding a genetic sequence;
- its therapeutic effect relates directly to the product of genetic expression of this sequence.
the EMA/CAT considers that the product falls within the definition of a gene therapy medicinal product